language Türkçe
Article 2023 · 13 citations

Bromelain protects against cisplatin-induced ocular toxicity through mitigating oxidative stress and inflammation

Ferah Okkay, Irmak, Okkay, Ufuk, Bayram, Cemil, Cicek, Betul, Sezen, Selma, Aydin, Ismail Cagri, Mendil, Ali Sefa, Hacimuftuoglu, Ahmet

Abstract

The aim of this study was to investigate the molecular, biochemical, and histopathological effects of bromelain, which has antioxidant and anti-inflammatory properties, against cisplatin-induced ocular toxicity. The groups were designed as (1) Control, (2) Cisplatin (7 mg/kg, intraperitoneally), (3) Cisplatin + Bromelain (50 mg/kg, orally for 14 consecutive days), (4) Cisplatin + Bromelain (100 mg/kg, orally for 14 consecutive days). The activity of total antioxidant capacity (TAC) and total oxidant status (TOS) and levels of reactive oxygen species (ROS), superoxide dismutase (SOD), malondialdehyde (MDA), interleukin-1 beta (IL-1 beta), IL-10, nuclear factor kappa B (NF-kappa B), tumor necrosis factor-alpha (TNF-alpha) and 8-OHdG were measured in ocular tissue. The mRNA expression of NF-kappa B and Caspase-3 was also evaluated. Also, ocular sections were evaluated histopathologically. Bromelain demonstrated a dose-dependent protective effect in cisplatin-induced toxicity by regulating oxidative stress, inflammation, and tissue damage. Our results suggested that bromelain may be a potential adjuvant that can protect the eye from cisplatin-induced toxicity.

Keywords
Bromelain cisplatin ocular toxicity rat oxidative stress inflammation NF-KAPPA-B RAT INHIBITION APOPTOSIS CYTOKINES INJURY CELLS RUTIN
WoS Categories
Chemistry, Multidisciplinary Pharmacology & Pharmacy Toxicology
Sustainable Development Goals
Citation
Journal
DRUG AND CHEMICAL TOXICOLOGY
Year
2023
Volume
46
Issue
1
Pages
69-76
ISSN
0148-0545
eISSN
1525-6014
DOI
10.1080/01480545.2021.2011308
WoS UID
WOS:000729677000001
Open via DOI